CCAAT/enhancer-binding protein α antagonizes transcriptional activity of hypoxia-inducible factor 1 α with direct protein–protein interaction

Hypoxia-inducible factor 1 (HIF-1), a master heterodimeric transcriptional regulator consisting of HIF-1alpha and HIF-1beta subunits for cellular response to hypoxia, plays an important role in carcinogenesis, while CCAAT/enhancer-binding protein alpha (C/EBPalpha) is proposed to act as a tumor suppressor in C/EBPalpha-expressing tissues. Previously, we reported that ectopically expressed HIF-1alpha protein interacts with and enhances transcriptional activity of C/EBPalpha, which favors leukemic cell differentiation. Here we further showed that such an interaction also occurred in their endogenously expressing state of leukemic U937 cells. Glutathione S-transferase pull-down assay proposed that the protein-protein interaction was direct, and transactivation domains of C/EBPalpha and the basic helix-loop-helix domain of HIF-1alpha were essential for such an interaction. More intriguingly, we provided the first demonstration that C/EBPalpha competed with HIF-1beta for direct binding to HIF-1alpha protein. Correspondingly, C/EBPalpha overexpression significantly inhibited the DNA-binding ability of HIF-1 and expressions of hypoxia-responsive element-driven luciferase and HIF-1-targeted genes vascular endothelial growth factor, glucose transporter-1 and phosphoglycerate kinase 1. In parallel, suppression of C/EBPalpha expression by specific small hairpin RNA increased DNA-binding ability of HIF-1 and expression of these HIF-1-targeted genes in leukemic U937 cells. These results would provide new insights for antitumor potential of C/EBPalpha protein.

[1]  Guoqiang Chen,et al.  Hypoxia-inducible factor-1α-induced differentiation of myeloid leukemic cells is its transcriptional activity independent , 2008, Oncogene.

[2]  G. Semenza,et al.  HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. , 2007, Cancer cell.

[3]  Fang Li,et al.  Regulation of HIF-1α Stability through S-nitrosylation , 2007 .

[4]  D. Tenen,et al.  Immunohistochemical analysis of C/EBPα in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: A correlative study of E3590 , 2007 .

[5]  Daniel G. Tenen,et al.  Transcription factors in myeloid development: balancing differentiation with transformation , 2007, Nature Reviews Immunology.

[6]  A. C. Williams,et al.  Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia , 2007, Nature Cell Biology.

[7]  A. Harris,et al.  Role of hypoxia-inducible factor-1alpha as a cancer therapy target. , 2006, Endocrine-related cancer.

[8]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[9]  G. Melillo,et al.  Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.

[10]  G. Semenza,et al.  Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia‐inducible factor 1 , 2006, Experimental physiology.

[11]  Rosa Bernardi,et al.  PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR , 2006, Nature.

[12]  O. Bernard,et al.  Functional analyses of the TEL-ARNT fusion protein underscores a role for oxygen tension in hematopoietic cellular differentiation , 2006, Oncogene.

[13]  B. Porse,et al.  C/EBPα: A tumour suppressor in multiple tissues? , 2006 .

[14]  H. Chung,et al.  Effects of Tiron, 4,5-dihydroxy-1,3-benzene disulfonic acid, on human promyelotic HL-60 leukemia cell differentiation and death. , 2006, Toxicology.

[15]  M. Déry,et al.  [HIF-1 activation during tumor progression: implications and consequences]. , 2006, Bulletin du cancer.

[16]  C. Plass,et al.  Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. , 2006, Journal of the National Cancer Institute.

[17]  Wei Liu,et al.  Hypoxia inducible factor-1alpha and leukemic cell differentiation. , 2006, Sheng li xue bao : [Acta physiologica Sinica].

[18]  W. Liu,et al.  Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. , 2006, Blood.

[19]  G. Camenisch,et al.  Integration of Oxygen Signaling at the Consensus HRE , 2005, Science's STKE.

[20]  Guoqiang Chen,et al.  Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1alpha protein. , 2005, Biochemical and biophysical research communications.

[21]  M. Lübbert,et al.  Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1α that augments transcriptional activity of CCAAT/enhancer-binding protein-α , 2005, Leukemia.

[22]  F. Rosenbauer,et al.  Role of Transcription Factors C/EBPα and PU.1 in Normal Hematopoiesis and Leukemia , 2005, International journal of hematology.

[23]  H. Phillip Koeffler,et al.  Down-Regulation and Growth Inhibitory Role of C/EBPα in Breast Cancer , 2005, Clinical Cancer Research.

[24]  R. Smart,et al.  Diminished Expression of C/EBPα in Skin Carcinomas Is Linked to Oncogenic Ras and Reexpression of C/EBPα in Carcinoma Cells Inhibits Proliferation , 2005, Cancer Research.

[25]  P. Sims,et al.  Protein kinase C (cid:1) mediates retinoic acid and phorbol myristate acetate–induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation , 2004 .

[26]  L. Huang,et al.  HIF‐1α induces cell cycle arrest by functionally counteracting Myc , 2004 .

[27]  G. Powis,et al.  Hypoxia inducible factor as a cancer drug target. , 2003, Current cancer drug targets.

[28]  M. Kurokawa,et al.  Role of AML1/Runx1 in the pathogenesis of hematological malignancies , 2003, Cancer science.

[29]  W. Liu,et al.  Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1α , 2003, Leukemia.

[30]  R. Johnson,et al.  HIF-1 in cell cycle regulation, apoptosis, and tumor progression. , 2003, Antioxidants & redox signaling.

[31]  Moon-Kyoung Bae,et al.  Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation , 2002, Cell.

[32]  D. Ramji,et al.  CCAAT/enhancer-binding proteins: structure, function and regulation. , 2002, The Biochemical journal.

[33]  M. Ebara,et al.  Decreased expression of the CCAAT/enhancer binding protein alpha gene involved in hepatocyte proliferation in human hepatocellular carcinomas. , 2002, International journal of molecular medicine.

[34]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[35]  K. Ozato,et al.  Transcription Factors that Regulate Growth and Differentiation of Myeloid Cells , 2001, International reviews of immunology.

[36]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[37]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[38]  G. Semenza.  HIF-1: mediator of physiological and pathophysiological responses to hypoxia. , 2000, Journal of applied physiology.

[39]  C Michiels,et al.  Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (review). , 2000, International journal of molecular medicine.

[40]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[41]  D. Mottet,et al.  Hypoxia‐induced activation of HIF‐1: role of HIF‐1α‐Hsp90 interaction , 1999 .

[42]  T. Naoe,et al.  Relationship Between Degradation of PML-RAR and Differentiation , 1999 .

[43]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[44]  D. Tenen,et al.  Multiple Functional Domains of AML1: PU.1 and C/EBPα Synergize with Different Regions of AML1 , 1998, Molecular and Cellular Biology.

[45]  D. Tenen,et al.  CCAAT/Enhancer Binding Protein α Is a Regulatory Switch Sufficient for Induction of Granulocytic Development from Bipotential Myeloid Progenitors , 1998, Molecular and Cellular Biology.

[46]  Y Fujii-Kuriyama,et al.  A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Semenza,et al.  Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[48]  D. Tenen,et al.  CCAAT Enhancer-Binding Protein ( C / EBP ) and AML 1 ( CBF a 2 ) Synergistically Activate the Macrophage Colony-Stimulating Factor Receptor Promoter , 1995 .

[49]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[50]  A. C. Williams,et al.  Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. , 2007, Nature cell biology.

[51]  P. Ratcliffe,et al.  Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. , 2007, The Biochemical journal.

[52]  M. Dewhirst,et al.  Regulation of HIF-1alpha stability through S-nitrosylation. , 2007, Molecular cell.

[53]  B. Porse,et al.  C/EBPalpha: a tumour suppressor in multiple tissues? , 2006, Biochimica et biophysica acta.

[54]  P. Boccuni,et al.  Combinatorial action of RUNX1 and PU.1 in the regulation of hematopoiesis. , 2006, Critical reviews in eukaryotic gene expression.

[55]  Rosa Bernardi,et al.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. , 2006, Nature.

[56]  R. Smart,et al.  Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. , 2005, Cancer research.

[57]  M. Lübbert,et al.  Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. , 2005, Leukemia.

[58]  J. Vadgama,et al.  Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  G. Powis,et al.  Hypoxia inducible factor-1alpha as a cancer drug target. , 2004, Molecular cancer therapeutics.

[60]  T. Naoe,et al.  Relationship between degradation of PML-RARalpha and differentiation. , 1999, Blood.

[61]  D. Mottet,et al.  Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. , 1999, FEBS letters.